Literature DB >> 33755526

Neurotrophic Keratopathy in Pediatric Patients.

C Scelfo1,2,3, I S Mantagos1,2.   

Abstract

Purpose: This review provides an overview of the causes and treatment of neurotrophic keratopathy in the pediatric population.
Methods: A thorough review of the current literature discussing neurotrophic keratopathy was conducted then summarized.
Results: Fourty-nine papers were reviewed. Congenital and acquired causes of neurotrophic keratopathy exist in the pediatric population. Both medical and surgical approaches to treatment have been trialed, albeit to a limited extent, in pediatric patients. Conservative treatment includes topical lubrication and antibiotics to prevent concurrent infectious ulcer formation. Various neurotrophic factors have been trialed in the form of serum drops to restore corneal sensation when conservative measures fail. Surgically, different corneal neurotization techniques have been developed whereby a donor nerve is routed to the anesthetized cornea to restore innervation and sensation. Conclusions: Advances in the treatment of neurotrophic keratopathy have made corneal reinnervation and restoration of vision more easily attainable in pediatric patients.

Entities:  

Keywords:  Cenegermin; nerve growth factor; neurotization; neurotrophic keratitis; neurotrophic keratopathy

Year:  2021        PMID: 33755526     DOI: 10.1080/08820538.2021.1896747

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  2 in total

Review 1.  Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets.

Authors:  Deanna H Dang; Kamran M Riaz; Dimitrios Karamichos
Journal:  Drugs       Date:  2022-01-13       Impact factor: 9.546

2.  Maternal serum eye drops to treat bilateral neurotrophic keratopathy in congenital corneal anesthesia: Case report and literature review.

Authors:  Giuseppe Giannaccare; Andrea Lucisano; Marco Pellegrini; Gianfranco Scuteri; Alessandra Mancini; Cristina Malaventura; Massimo Busin; Vincenzo Scorcia
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.